Fig. 1
From: Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
Waterfall plot depicting best response as a percent change in target lesion size in all evaluable patients. Patients previously treated with gemcitabine are indicated with blue
